Article Details

Blueprint Medicines Q2 Revenues Increase More Than 200 Percent

Retrieved on: 2021-07-29 17:10:45

Tags for this article:

Click the tags to see associated articles and topics

Blueprint Medicines Q2 Revenues Increase More Than 200 Percent. View article details on hiswai:

Excerpt

A year ago, Roche paid Blueprint $775M for certain rights to pralsetinib. At the end of Q2, Blueprint reached a milestone in that joint commercialization ...

Article found on: www.precisiononcologynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up